The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,
ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The deal will see ImmunoGen’s follow-on pipeline of next-generation ADCs complement the ADC platform and
The partnership has been formed through Astella’s wholly-owned subsidiary Xyphos Biosciences. They will assess the potential of antibodies, developed by Phenomic and designed for a novel tumour stroma
Schizophrenia is a long-lasting mental illness that can significantly affect a person’s thoughts, emotions, and behaviours. It impacts nearly 24 million people globally, with 2.8 million affected in
The partnership will utilise Accutar’s artificial intelligence (AI) platform and Evommune’s expertise to design and develop novel oral small molecule treatments for targets, which are the root cause
The Hemophilia A programme integrates the Sernova Cell Pouch with a patient’s cells, eliminating the need for immunosuppression medications. This treatment aims to substitute Factor VIII (FVIII), a
The company has filed the applications based on Revascor’s data from a randomised, blinded, controlled prospective study carried out at a single centre in the US involving 19
A therapy platform developed by T3 Pharma using engineered Yersinia enterocolitica bacteria, delivers immune-modulating proteins to cancer cells and tumour micro-environments, sparing healthy tissues. The bacteria can be
Claimed to be the first vaccine against the disease to receive FDA’s marketing approval, IXCHIQ uses Albumedix’ Recombumin. Recombumin is an animal origin-free recombinant human albumin and is
The oral CDK2 inhibitor from Ensem is an investigational new drug (IND) application-ready asset. BeiGene R&D global head Lai Wang said: “We are committed to developing novel molecules
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.